Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval
60-Word AI Digest
Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval. Reporting by CNBC highlights major developments in this space as key stakeholders evaluate broader implications. Further data and contextual analysis are actively being published. Access the full coverage dispatch below for complete documentation.
Key Takeaways
- Lilly plans to file by the end of the year for U.S.
- approval of the daily pill for moderate-to-severe obstructive sleep apnea in adults with obesity.
- Full details and original dispatch available below.
Lilly plans to file by the end of the year for U.S. approval of the daily pill for moderate-to-severe obstructive sleep apnea in adults with obesity.
Original Publisher Attribution
This summary was curated from CNBC.